DK149856C - Fremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf - Google Patents

Fremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf

Info

Publication number
DK149856C
DK149856C DK158481A DK158481A DK149856C DK 149856 C DK149856 C DK 149856C DK 158481 A DK158481 A DK 158481A DK 158481 A DK158481 A DK 158481A DK 149856 C DK149856 C DK 149856C
Authority
DK
Denmark
Prior art keywords
procedure
preparation
acceptable salts
physiologically acceptable
trisubstituted xanthines
Prior art date
Application number
DK158481A
Other languages
English (en)
Other versions
DK149856B (da
DK158481A (da
Inventor
Georges Philippossian
Marc Enslen
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of DK158481A publication Critical patent/DK158481A/da
Priority to DK78986A priority Critical patent/DK152127C/da
Publication of DK149856B publication Critical patent/DK149856B/da
Application granted granted Critical
Publication of DK149856C publication Critical patent/DK149856C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK158481A 1980-05-02 1981-04-08 Fremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf DK149856C (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK78986A DK152127C (da) 1980-05-02 1986-02-20 Analogifremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH343180 1980-05-02
CH343180A CH643260A5 (fr) 1980-05-02 1980-05-02 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.

Publications (3)

Publication Number Publication Date
DK158481A DK158481A (da) 1981-11-03
DK149856B DK149856B (da) 1986-10-13
DK149856C true DK149856C (da) 1987-05-25

Family

ID=4255824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK158481A DK149856C (da) 1980-05-02 1981-04-08 Fremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf

Country Status (21)

Country Link
US (2) US4469698A (da)
EP (1) EP0039780B1 (da)
JP (1) JPS56169690A (da)
AU (1) AU539258B2 (da)
CA (1) CA1155841A (da)
CH (1) CH643260A5 (da)
CS (1) CS221829B2 (da)
DD (1) DD158776A5 (da)
DE (1) DE3169784D1 (da)
DK (1) DK149856C (da)
ES (1) ES502414A0 (da)
FI (1) FI68831C (da)
GB (1) GB2075505B (da)
HK (1) HK49985A (da)
HU (1) HU185256B (da)
IL (1) IL62641A (da)
MX (1) MX5974E (da)
MY (1) MY8500517A (da)
PH (2) PH17137A (da)
PL (1) PL135383B1 (da)
SG (1) SG20884G (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5338741A (en) * 1986-10-27 1994-08-16 Nestec S.A. 1-hydroxyalkylxanthines and medicaments containing them
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
EP0407651A3 (en) * 1989-07-10 1991-08-07 J. Uriach & Cia. S.A. Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
AU4527996A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
FR2741455B1 (fr) * 1995-11-21 1997-12-26 Alcatel Optronics Procede de formation d'une nappe de fibres optiques inclinees a dioptres de couplage
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US9221821B2 (en) 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB701242A (en) * 1950-11-28 1953-12-23 Searle & Co Improvements in or relating to disubstituted 6-amino-1,2,3,4-tetrahydro-2,4-pyrimidinediones and methods of preparing the same
US2673848A (en) * 1951-12-29 1954-03-30 Searle & Co 3-alkenylxanthines and their lower 1-alkyl derivatives
GB759174A (en) * 1952-11-07 1956-10-17 Geigy Ag J R Improvements in diuretic acting xanthine derivatives
GB766754A (en) * 1954-01-27 1957-01-23 Geigy Ag J R New derivatives of 1.3-disubstituted and 1.3.8-trisubstituted xanthines and processes for their production
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
US3740433A (en) * 1971-10-01 1973-06-19 Squibb & Sons Inc Anti-anxiety composition and method of use
CA1077932A (en) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.

Also Published As

Publication number Publication date
IL62641A (en) 1985-01-31
DE3169784D1 (en) 1985-05-15
HU185256B (en) 1984-12-28
EP0039780B1 (fr) 1985-04-10
ES8207532A1 (es) 1982-10-01
CS221829B2 (en) 1983-04-29
DD158776A5 (de) 1983-02-02
GB2075505B (en) 1984-01-11
FI68831B (fi) 1985-07-31
SG20884G (en) 1985-01-04
FI68831C (fi) 1985-11-11
GB2075505A (en) 1981-11-18
PL230936A1 (da) 1982-06-07
CA1155841A (en) 1983-10-25
FI811067L (fi) 1981-11-03
PL135383B1 (en) 1985-10-31
CH643260A5 (fr) 1984-05-30
ES502414A0 (es) 1982-10-01
JPS56169690A (en) 1981-12-26
AU539258B2 (en) 1984-09-20
US4469698A (en) 1984-09-04
DK149856B (da) 1986-10-13
PH17137A (en) 1984-06-04
PH17660A (en) 1984-10-25
IL62641A0 (en) 1981-06-29
EP0039780A1 (fr) 1981-11-18
US4581451A (en) 1986-04-08
HK49985A (en) 1985-07-05
MX5974E (es) 1984-09-11
DK158481A (da) 1981-11-03
AU6961781A (en) 1981-11-05
MY8500517A (en) 1985-12-31

Similar Documents

Publication Publication Date Title
DK149856C (da) Fremgangsmaade til fremstilling af 1,3-di- eller 1,3,8-trisubstituerede xanthiner eller fysiologisk acceptable salte deraf
DK405477A (da) Fremgangsmaade til fremstilling af 5-alkoxyimidazo(1,2-a) quinolin-2-carboxylsyrer eller estere eller kationiske salte deraf
DK552581A (da) Fremgangsmaade til fremstilling af 3-pyridylaklyl-indol-forbindelser eller farmaceutisk acceptable salte deraf
DK161968C (da) Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf
DK503080A (da) Fremgangsmaade til fremstilling af imdazolderivater eller salte deraf
DK70083D0 (da) Fremgangsmade til fremstilling af pyrroleddikesyreamider eller salte deraf
DK473182A (da) Fremgangsmaade til fremstilling af 3-aminopregn-5-enderivater eller salte deraf
DK493083A (da) Fremgangsmaade til fremstilling af 4-oxo-1,4-dihydronicotinsyrederivater eller salte deraf
DK143183C (da) Analogifremgangsmaade til fremstilling af 1h-pyrazolo(3,4-b)pyridiner eller fysiologisk acceptable salte deraf
DK76578A (da) Fremgangsmaade til fremstilling af d,1-5-methyltetrahydrofolinsyre eller salte deraf
DK118482A (da) Fremgangsmaade til fremstilling af 2,4,5-trisubstituerede thiazoler eller salte deraf
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK75878A (da) Fremgangsmaade til fremstilling af 20,21,-di-noreburnameninderivater eller additionssalte deraf
DK324979A (da) Fremgangsmaade til fremstilling af imidazoquinoxaliner eller salte deraf
DK463083A (da) Fremgangsmaade til fremstilling af benzofuraner eller 2,3-dihydro-benzofuraner eller farmaceutisk acceptable salte deraf
DK134580A (da) Fremgangsmaade til fremstilling af 2,6-diaminonebulariner eller syreadditionssalte deraf
DK164379A (da) Fremgangsmaade til fremstilling af 7-methoxy-5-oxo-5h-thiazolo(2,3-b)quinazolin-2-carboxylsyre eller farmaceutisk anvendelige salte deraf
DK232677A (da) Fremgangsmade til fremstilling af dihydro eller tetrahydroiminothiaziner eller farmaceutisk acceptable salte deraf
DK158227C (da) Analogifremgangsmaade til fremstilling af substituerede imidazooe1,5-aaapyridiner eller 5,6,7,8-tetrahydroderivater deraf eller salte deraf
DK232877A (da) Fremgangsmade til fremstilling af 2-imino-3-aminothiazolidiner eller farmaceutisk acceptable salte deraf
DK157021C (da) Analogifremgangsmaade til fremstilling af 2,3-polymethylen-4-oxo-4h-pyrido- eller -azepinooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf
DK149823C (da) Fremgangsmaade til fremstilling af kijanimicin eller farmaceutisk acceptable salte heraf
DK224381A (da) Fremgangsmaade til fremstilling af benzazolderivater eller salte deraf
DK143403C (da) Analogifremgangsmaade til fremstilling af 8-(1h-tetrazol-5-yl)-11h-pyrido(2,1-b)quinazolin-11-oner eller salte deraf
DK153539C (da) Fremgangsmaade til fremstilling af 3,3-dimethyl-2-oxosmoersyre eller salte deraf

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment
PBP Patent lapsed
PBP Patent lapsed